Of the tracked stories, 1 of 2 also mention CalMatters, the most common co-covered peer. Source depth averages 1.5 original sources per story, versus 6.4 across the same-window beat baseline. That works out to roughly 1.4 stories per week across a 10-day span.
Coverage balanceBalanced directional read. Positive and negative coverage are within 0 percentage points.
50% positive
50% negative
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about U.S. Department of Justice
Of the tracked stories, 1 of 2 also mention CalMatters, the most common co-covered peer. Source depth averages 1.5 original sources per story, versus 6.4 across the same-window beat baseline. That works out to roughly 1.4 stories per week across a 10-day span. At 8.5, the average consequence score sits above the same-window beat average of 6.7. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. U.S. Department of Justice appears in 2 tracked Healthcare stories published from July 12, 2026 through July 21, 2026.
Stories tracked
2
Per week
1.4
Sources per story
1.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 79 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering U.S. Department of Justice. Shared-story counts are live from our verified record — not editorial picks.
Nearly $2 billion in health-related research grants at UC were terminated via keyword scans for terms like 'vaccine hesitancy' and 'COVID-19,' according to court filings. The cancellations jeopardize critical public health studies and clinical trials.
MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling.